Vergent Bioscience to present phase 2 clinical data for VGT-309 at IASLC 2023 World Conference on Lung Cancer

Aug. 17, 2023
Researchers will share findings from the first surgical study using a novel, tumor-targeted fluorescent imaging agent designed to make lung cancer surgery more successful by improving the intraoperative visualization of tumors.

Vergent Bioscience and its wholly owned subsidiary Vergent Bioscience Australia Pty Ltd, announced that new clinical data from a Phase 2 study of the company’s investigational agent VGT-309 will be presented at the 2023 World Conference on Lung Cancer (#WCLC23) hosted by the International Association for the Study of Lung Cancer (IASLC), taking place September 9-12, 2023, in Singapore. 

Early Phase 1 and 2 clinical trials evaluating VGT-309 in lung cancer yielded compelling safety and efficacy data that support the agent’s ability to help surgeons see difficult-to-find or previously undetected tumors in real-time, ensuring all tumor tissue is removed during minimally invasive (MIS) and robotic-assisted surgical procedures. 

Following are details about the VGT-309 presentation at the 2023 WCLC: 

Title: Results from a Phase II trial of a Tumor-Activated Fluorescent Molecule for the Intra-Operative Identification of Lung Cancer 

Presenter: Professor Gavin M. Wright, Ph.D., director of Surgical Oncology, St. Vincent’s Hospital, Melbourne, Australia 

Abstract/Session: #844; MA11.06New Technology and Innovations in Early-Stage Lung Cancer 

Date/Time: 2:30 - 3:30 PM Singapore/2:30 – 3:30 AM ET, September 11, 2023 

Location: Suntec Singapore Convention & Exhibition Centre, Room 405C 

Read the full release on Businesswire